4.7 Review

Screening for Chronic Obstructive Pulmonary Disease US Preventive Services Task Force Reaffirmation Recommendation Statement

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 327, 期 18, 页码 1806-1811

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2022.5692

关键词

-

向作者/读者索取更多资源

The US Preventive Services Task Force has updated its recommendation on screening for COPD in asymptomatic adults, stating that it has no net benefit.
IMPORTANCE Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US. OBJECTIVE To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults. POPULATION Asymptomatic adults who do not recognize or report respiratory symptoms. EVIDENCE ASSESSMENT Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit. RECOMMENDATION The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据